Biotech Values

[Doc328]

Though I would think regular use would increase risk there is actually not that much data. Here is a meta analysis I found. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085407/

FWIW I think the recent article has a lot of flaws. As a couple people pointed out the severity of comorbidities was lot taken k to account. I think the use of a single top academic practice causes severe referral bias. (Cross section of people within ten miles but wealthier patients from the whole country who might travel to Harvard and have better care and control of their comorbidities). Most patients with NAION do not need referrral to a top eye program. Many ophthalmologists practice solo or small groups and collecting cohorts representative of the national population would not be easy. In the US a Kaiser or similar captured large population might best provide evidence or lack of evidence of an association.